{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T02:18:10Z","timestamp":1791253090343,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Karolinska Institutet (Karolinska Institute)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Kynurenine pathway (KP) activation by the enzymatic activity of indoleamine 2,3-dioxygenase1 (IDO1) and kynurenine (KYN) production represents an attractive target for reducing tumour progression and improving anti-tumour immunity in multiple cancers. However, immunomodulatory properties of other KP metabolites such as 3-hydroxy kynurenine (3-HK) and kynurenic acid (KYNA) are poorly understood. The association of the kynurenine metabolic pathway with T-cell status in the tumour microenvironment were characterized, using gene expression data of 368 cutaneous skin melanoma (SKCM) patients from the TCGA cohort. Based on the identified correlations, we characterized the production of KYN, 3-HK, and KYNA <jats:italic>in vitro<\/jats:italic> using melanoma-derived cell lines and primary CD4+ CD25\u2212 T-cells. Activation of the CD4+ T-cells produced IFN\u03b3, which yielded increased levels of KYN and KYNA. Concurrently, kynurenine 3-monooxygenase (KMO) expression and proliferation of CD4+ T-cells were reduced, whereas exhaustion markers such as PD-L1, AHR, FOXP3, and CTLA4 were increased. Additionally, an analysis of the correlation network reconstructed using TCGA-SKCM emphasized KMO and KYNU with high variability among BRAF wild-type compared with V600E, which underscored their role in distinct CD4+ T-cell behavior in tumour immunity. Our results suggest that, in addition to IDO1, there is an alternative immune regulatory mechanism associated with the lower KMO expression and the higher KYNA production, which contributes to dysfunctional effector CD4+ T-cell response.<\/jats:p>","DOI":"10.1038\/s41598-019-48635-x","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T10:02:54Z","timestamp":1566381774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Exhaustion of CD4+ T-cells mediated by the Kynurenine Pathway in Melanoma"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8114-7041","authenticated-orcid":false,"given":"Soudabeh","family":"Rad Pour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Morikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsis A.","family":"Kiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muyi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowhar","family":"Shafi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingmei","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Baumgartner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0087-116X","authenticated-orcid":false,"given":"Daniel F. J.","family":"Ketelhuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Anas","family":"Kamleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-0653","authenticated-orcid":false,"given":"Craig E.","family":"Wheelock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Lundqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Hansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesper","family":"Tegn\u00e9r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"48635_CR1","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27, 6199\u20136206, https:\/\/doi.org\/10.1200\/JCO.2009.23.4799 (2009).","journal-title":"J Clin Oncol"},{"key":"48635_CR2","doi-asserted-by":"publisher","first-page":"15003","DOI":"10.1038\/nrdp.2015.3","volume":"1","author":"D Schadendorf","year":"2015","unstructured":"Schadendorf, D. et al. Melanoma. Nat Rev Dis Primers 1, 15003, https:\/\/doi.org\/10.1038\/nrdp.2015.3 (2015).","journal-title":"Nat Rev Dis Primers"},{"key":"48635_CR3","unstructured":"Farma, W. H. W. A. J. M. Cutaneous Melanoma: Etiology and Therapy (2017)."},{"key":"48635_CR4","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1038\/nature12213","volume":"499","author":"MS Lawrence","year":"2013","unstructured":"Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214\u2013218, https:\/\/doi.org\/10.1038\/nature12213 (2013).","journal-title":"Nature"},{"key":"48635_CR5","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc3973","volume":"15","author":"I Melero","year":"2015","unstructured":"Melero, I. et al. Evolving synergistic combinations of targeted immunotherapies to combat cancer. Nat Rev Cancer 15, 457\u2013472, https:\/\/doi.org\/10.1038\/nrc3973 (2015).","journal-title":"Nat Rev Cancer"},{"key":"48635_CR6","doi-asserted-by":"publisher","first-page":"4275","DOI":"10.1073\/pnas.0915174107","volume":"107","author":"MA Curran","year":"2010","unstructured":"Curran, M. A., Montalvo, W., Yagita, H. & Allison, J. P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 107, 4275\u20134280, https:\/\/doi.org\/10.1073\/pnas.0915174107 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"48635_CR7","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd.2018.67","volume":"17","author":"A Mullard","year":"2018","unstructured":"Mullard, A. IDO takes a blow. Nat Rev Drug Discov 17, 307, https:\/\/doi.org\/10.1038\/nrd.2018.67 (2018).","journal-title":"Nat Rev Drug Discov"},{"key":"48635_CR8","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.4049\/jimmunol.1402669","volume":"194","author":"M Zanetti","year":"2015","unstructured":"Zanetti, M. Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. J Immunol 194, 2049\u20132056, https:\/\/doi.org\/10.4049\/jimmunol.1402669 (2015).","journal-title":"J Immunol"},{"key":"48635_CR9","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/2326-6066.CIR-13-0216","volume":"2","author":"HJ Kim","year":"2014","unstructured":"Kim, H. J. & Cantor, H. CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2, 91\u201398, https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0216 (2014).","journal-title":"Cancer Immunol Res"},{"key":"48635_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2013.12.005","volume":"27","author":"H Nishikawa","year":"2014","unstructured":"Nishikawa, H. & Sakaguchi, S. Regulatory T cells in cancer immunotherapy. Curr Opin Immunol 27, 1\u20137, https:\/\/doi.org\/10.1016\/j.coi.2013.12.005 (2014).","journal-title":"Curr Opin Immunol"},{"key":"48635_CR11","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1084\/jem.20020121","volume":"196","author":"G Frumento","year":"2002","unstructured":"Frumento, G. et al. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med 196, 459\u2013468, https:\/\/doi.org\/10.1084\/jem.20020121 (2002).","journal-title":"J Exp Med"},{"key":"48635_CR12","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/nature10491","volume":"478","author":"CA Opitz","year":"2011","unstructured":"Opitz, C. A. et al. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor. Nature 478, 197\u2013203, https:\/\/doi.org\/10.1038\/nature10491 (2011).","journal-title":"Nature"},{"key":"48635_CR13","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nm934","volume":"9","author":"C Uyttenhove","year":"2003","unstructured":"Uyttenhove, C. et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9, 1269\u20131274, https:\/\/doi.org\/10.1038\/nm934 (2003).","journal-title":"Nat Med"},{"key":"48635_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1126\/science.281.5380.1191","volume":"281","author":"DH Munn","year":"1998","unstructured":"Munn, D. H. et al. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281, 1191\u20131193, https:\/\/doi.org\/10.1126\/science.281.5380.1191 (1998).","journal-title":"Science"},{"key":"48635_CR15","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1182\/blood-2009-09-246124","volume":"115","author":"X Liu","year":"2010","unstructured":"Liu, X. et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115, 3520\u20133530, https:\/\/doi.org\/10.1182\/blood-2009-09-246124 (2010).","journal-title":"Blood"},{"key":"48635_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.3389\/fimmu.2013.00116","volume":"4","author":"DA Wainwright","year":"2013","unstructured":"Wainwright, D. A., Dey, M., Chang, A. & Lesniak, M. S. Targeting Tregs in Malignant Brain Cancer: Overcoming IDO. Front Immunol 4, 116, https:\/\/doi.org\/10.3389\/fimmu.2013.00116 (2013).","journal-title":"Front Immunol"},{"key":"48635_CR17","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.imlet.2007.06.001","volume":"111","author":"M Zamanakou","year":"2007","unstructured":"Zamanakou, M., Germenis, A. E. & Karanikas, V. Tumor immune escape mediated by indoleamine 2,3-dioxygenase. Immunol Lett 111, 69\u201375, https:\/\/doi.org\/10.1016\/j.imlet.2007.06.001 (2007).","journal-title":"Immunol Lett"},{"key":"48635_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10753-013-9733-9","volume":"37","author":"W Dabrowski","year":"2014","unstructured":"Dabrowski, W., Kocki, T., Pilat, J., Parada-Turska, J. & Malbrain, M. L. Changes in plasma kynurenic acid concentration in septic shock patients undergoing continuous veno-venous haemofiltration. Inflammation 37, 223\u2013234, https:\/\/doi.org\/10.1007\/s10753-013-9733-9 (2014).","journal-title":"Inflammation"},{"key":"48635_CR19","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s00702-011-0763-x","volume":"119","author":"F Moroni","year":"2012","unstructured":"Moroni, F., Cozzi, A., Sili, M. & Mannaioni, G. Kynurenic acid: a metabolite with multiple actions and multiple targets in brain and periphery. J Neural Transm (Vienna) 119, 133\u2013139, https:\/\/doi.org\/10.1007\/s00702-011-0763-x (2012).","journal-title":"J Neural Transm (Vienna)"},{"key":"48635_CR20","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.immuni.2005.03.013","volume":"22","author":"DH Munn","year":"2005","unstructured":"Munn, D. H. et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. Immunity 22, 633\u2013642, https:\/\/doi.org\/10.1016\/j.immuni.2005.03.013 (2005).","journal-title":"Immunity"},{"key":"48635_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.4161\/onci.21716","volume":"1","author":"R Metz","year":"2012","unstructured":"Metz, R. et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology 1, 1460\u20131468, https:\/\/doi.org\/10.4161\/onci.21716 (2012).","journal-title":"Oncoimmunology"},{"key":"48635_CR22","doi-asserted-by":"publisher","first-page":"4065","DOI":"10.1158\/0008-5472.CAN-17-0090","volume":"77","author":"LT Wang","year":"2017","unstructured":"Wang, L. T. et al. Intestine-Specific Homeobox Gene ISX Integrates IL6 Signaling, Tryptophan Catabolism, and Immune Suppression. Cancer Res 77, 4065\u20134077, https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0090 (2017).","journal-title":"Cancer Res"},{"key":"48635_CR23","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-018-0644-y","volume":"11","author":"M Liu","year":"2018","unstructured":"Liu, M. et al. Targeting the IDO1 pathway in cancer: from bench to bedside. J Hematol Oncol 11, 100, https:\/\/doi.org\/10.1186\/s13045-018-0644-y (2018).","journal-title":"J Hematol Oncol"},{"key":"48635_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.4049\/jimmunol.1502615","volume":"197","author":"Q Li","year":"2016","unstructured":"Li, Q., Harden, J. L., Anderson, C. D. & Egilmez, N. K. Tolerogenic Phenotype of IFN-gamma-Induced IDO+ Dendritic Cells Is Maintained via an Autocrine IDO-Kynurenine\/AhR-IDO Loop. J Immunol 197, 962\u2013970, https:\/\/doi.org\/10.4049\/jimmunol.1502615 (2016).","journal-title":"J Immunol"},{"key":"48635_CR25","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2006-07-036863","volume":"109","author":"A Curti","year":"2007","unstructured":"Curti, A. et al. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25\u2212 into CD25+ T regulatory cells. Blood 109, 2871\u20132877, https:\/\/doi.org\/10.1182\/blood-2006-07-036863 (2007).","journal-title":"Blood"},{"key":"48635_CR26","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nature13323","volume":"511","author":"A Bessede","year":"2014","unstructured":"Bessede, A. et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature 511, 184\u2013190, https:\/\/doi.org\/10.1038\/nature13323 (2014).","journal-title":"Nature"},{"key":"48635_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/bjc.2016.412","volume":"116","author":"D Anastasiou","year":"2017","unstructured":"Anastasiou, D. Tumour microenvironment factors shaping the cancer metabolism landscape. Br J Cancer 116, 277\u2013286, https:\/\/doi.org\/10.1038\/bjc.2016.412 (2017).","journal-title":"Br J Cancer"},{"key":"48635_CR28","doi-asserted-by":"publisher","first-page":"19961","DOI":"10.1073\/pnas.1014465107","volume":"107","author":"NT Nguyen","year":"2010","unstructured":"Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci USA 107, 19961\u201319966, https:\/\/doi.org\/10.1073\/pnas.1014465107 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"48635_CR29","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.3389\/fimmu.2017.01957","volume":"8","author":"E Wirthgen","year":"2017","unstructured":"Wirthgen, E., Hoeflich, A., Rebl, A. & Gunther, J. Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions. Front Immunol 8, 1957, https:\/\/doi.org\/10.3389\/fimmu.2017.01957 (2017).","journal-title":"Front Immunol"},{"key":"48635_CR30","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2174\/092986712800167365","volume":"19","author":"L Szalardy","year":"2012","unstructured":"Szalardy, L. et al. Mitochondrial Disturbances, Tryptophan Metabolites and Neurodegeneration: Medicinal Chemistry Aspects. Current Medicinal Chemistry 19, 1899\u20131920, https:\/\/doi.org\/10.2174\/092986712800167365 (2012).","journal-title":"Current Medicinal Chemistry"},{"key":"48635_CR31","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.biopsych.2016.12.011","volume":"82","author":"S Erhardt","year":"2017","unstructured":"Erhardt, S. et al. Adaptive and Behavioral Changes in Kynurenine 3-Monooxygenase Knockout Mice: Relevance to Psychotic Disorders. Biol Psychiatry 82, 756\u2013765, https:\/\/doi.org\/10.1016\/j.biopsych.2016.12.011 (2017).","journal-title":"Biol Psychiatry"},{"key":"48635_CR32","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1002\/eji.201242779","volume":"43","author":"GL Stephens","year":"2013","unstructured":"Stephens, G. L. et al. Kynurenine 3-monooxygenase mediates inhibition of Th17 differentiation via catabolism of endogenous aryl hydrocarbon receptor ligands. Eur J Immunol 43, 1727\u20131734, https:\/\/doi.org\/10.1002\/eji.201242779 (2013).","journal-title":"Eur J Immunol"},{"key":"48635_CR33","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh, I. et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science 352, 189\u2013196, https:\/\/doi.org\/10.1126\/science.aad0501 (2016).","journal-title":"Science"},{"key":"48635_CR34","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.neuropharm.2018.06.003","volume":"138","author":"M Tufvesson-Alm","year":"2018","unstructured":"Tufvesson-Alm, M. et al. Importance of kynurenine 3-monooxygenase for spontaneous firing and pharmacological responses of midbrain dopamine neurons: Relevance for schizophrenia. Neuropharmacology 138, 130\u2013139, https:\/\/doi.org\/10.1016\/j.neuropharm.2018.06.003 (2018).","journal-title":"Neuropharmacology"},{"key":"48635_CR35","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/2051-1426-2-3","volume":"2","author":"S Spranger","year":"2014","unstructured":"Spranger, S. et al. Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2, 3, https:\/\/doi.org\/10.1186\/2051-1426-2-3 (2014).","journal-title":"J Immunother Cancer"},{"key":"48635_CR36","doi-asserted-by":"publisher","unstructured":"Gangadhar, T. C. et al. Preliminary results from a Phase I\/II study of epacadostat (incb024360) in combination with pembrolizumab in patients with selected advanced cancers. Journal for ImmunoTherapy of Cancer 3, https:\/\/doi.org\/10.1186\/2051-1426-3-S2-O7 (2015).","DOI":"10.1186\/2051-1426-3-S2-O7"},{"key":"48635_CR37","doi-asserted-by":"publisher","first-page":"175","DOI":"10.4137\/IJTR.S6225","volume":"3","author":"AA Badawy","year":"2010","unstructured":"Badawy, A. A. & Morgan, C. J. Rapid Isocratic Liquid Chromatographic Separation and Quantification of Tryptophan and Six kynurenine Metabolites in Biological Samples with Ultraviolet and Fluorimetric Detection. Int J Tryptophan Res 3, 175\u2013186, https:\/\/doi.org\/10.4137\/IJTR.S6225 (2010).","journal-title":"Int J Tryptophan Res"},{"key":"48635_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.semcdb.2016.01.012","volume":"51","author":"NA Kiani","year":"2016","unstructured":"Kiani, N. A., Zenil, H., Olczak, J. & Tegner, J. Evaluating network inference methods in terms of their ability to preserve the topology and complexity of genetic networks. Semin Cell Dev Biol 51, 44\u201352, https:\/\/doi.org\/10.1016\/j.semcdb.2016.01.012 (2016).","journal-title":"Semin Cell Dev Biol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48635-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48635-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48635-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T12:50:34Z","timestamp":1671281434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-48635-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["48635"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-48635-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"12 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"12150"}}